Since the CTLA-4 pathway functions in secondary lymphoid organs while the PD-L1 pathway works within the TME, targeting CTLA-4 and PD-L1 simultaneously using bsAbs may enhance the antitumor benefit for cancer immunotherapy. Here, CTLA4 is linked to cancer.